Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Erdafitinib + Quisinostat |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Erdafitinib | Balversa | JNJ-42756493 | FGFR Inhibitor (Pan) 26 | Balversa (erdafitinib) selectively inhibits FGFR1-4, resulting in decreased downstream signaling, and potentially leading to reduced growth of tumors with activated FGFR signaling (PMID: 28341788, PMID: 28965185). Balversa (erdafitinib) is FDA approved for use in patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations (FDA.gov). |
Quisinostat | JNJ-26481585|JNJ-6481585 | HDAC Inhibitor 45 | Quisinostat (JNJ-26481585) is a second-generation HDAC inhibitor, which increases histone acetlyation, and may increase tumor cell apoptosis and inhibit tumor growth (PMID: 24038993, PMID: 19861438, PMID: 31784862). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
FGFR3 S249C | urinary bladder cancer | sensitive | Erdafitinib + Quisinostat | Preclinical - Cell culture | Actionable | In a preclinical study, the combination of Balversa (erdafitinib) and Quisinostat (JNJ-26481585) synergistically inhibited viability in a bladder cancer cell line harboring FGFR3 S249C in culture (PMID: 37479885). | 37479885 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|